Long-Term Pertuzumab Outcomes in HER2+ Breast Cancer: Insights from APHINITY 8-Year Data and NeoSphere Pooled Analysis

Video content above is prompted by the following:

• Please provide some background on APHINITY 8-Year follow up data evaluating pertuzumab with adjuvant trastuzumab and chemotherapy in early HER2+ breast cancer.
  • With a median follow up of 8.4 years, what are your impressions of the long-term safety and efficacy profile of pertuzumab?
  • Is the IDFS benefit observed with pertuzumab sustained over the extended follow-up period?
  • Does the addition of pertuzumab have a positive impact on quality of life for patients with HER2-positive early breast cancer, beyond just extending IDFS?
• Please review the rationale and study design for the NeoSphere pooled analysis study and discuss implications of these data on treatment landscape.
  • Which treatment combinations were investigated and how did efficacy outcomes vary between the treatment arms? What are your impressions of these data?
  • How did tumor size, node involvement, or biomarker positivity affect efficacy outcomes?
  • What are your impressions of the safety data?